Castle Biosciences INC Form 4 insider transactions

Castle Biosciences' Chief Commercial Officer, Tobin W. Juvenal, sold 700 shares of common stock for approximately $24,773 under a pre-arranged 10b5-1 trading plan.

Castle Biosciences' Chief Operating Officer, Kristen M. Oelschlager, sold 18,932 shares of common stock for approximately $35.1 per share under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences' President and CEO, Derek J. Maetzold, sold 9,373 shares of common stock in early November 2025, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences' Chief Operating Officer, Kristen M Oelschlager, reported the sale of 12,678 shares of common stock for approximately $25.04 per share.

Castle Biosciences' Chief Operating Officer Kristen M Oelschlager filed an amended Form 4 to correct details regarding an indirect sale of 18,007 common shares.

Castle Biosciences President and CEO Derek J. Maetzold sold 1,339 shares of common stock for approximately $22.44 per share under a pre-arranged 10b5-1 plan.

Castle Biosciences CEO Derek J. Maetzold sold 1,339 shares of common stock for $22.58 per share under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences CEO Derek J. Maetzold sold 1,339 shares of common stock for approximately $21.97 per share under a pre-arranged trading plan.

Castle Biosciences' President and CEO, Derek J. Maetzold, sold 1,339 shares of common stock for approximately $32,000 as part of a pre-arranged trading plan.

Castle Biosciences' Chief Operating Officer, Kristen M. Oelschlager, sold 12,677 shares of common stock for $22.019 per share under a pre-arranged Rule 10b5-1 plan.

Castle Biosciences' Chief Operating Officer, Kristen M. Oelschlager, sold 18,007 shares of common stock for a weighted-average price of $21.69 per share.

Castle Biosciences CEO Derek Maetzold sold 1,339 shares of common stock for $20.04 per share under a pre-arranged 10b5-1 trading plan.

Castle Biosciences' President and CEO, Derek J. Maetzold, sold 43,019 shares of common stock for approximately $839,000 through a pre-arranged Rule 10b5-1 plan.

Castle Biosciences CEO Derek J. Maetzold reported the exercise of performance-based stock units and subsequent tax-related share disposals, alongside various trust-related share transfers.

Castle Biosciences CFO Frank Stokes acquired 9,744 shares through PSU vesting and subsequently sold 4,356 shares for tax purposes.

Castle Biosciences' Chief Operating Officer, Kristen M. Oelschlager, converted performance-based stock units into common stock and subsequently sold shares to cover tax obligations.

Castle Biosciences' Chief Commercial Officer, Tobin W. Juvenal, reported the vesting of performance-based stock units and a subsequent sale of shares for tax purposes.

Castle Biosciences' President and CEO, Derek J. Maetzold, sold 22,576 shares of common stock for approximately $20.3 per share on June 27, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

A recent SEC Form 4 filing reveals that G. Bradley Cole, a Director at Castle Biosciences Inc., acquired common stock through the vesting of Restricted Stock Units and received a new RSU grant, increasing his direct beneficial ownership.

Castle Biosciences Director Daniel Bradbury has reported changes in his beneficial ownership, including the vesting of 8,673 Restricted Stock Units into common stock and the grant of 13,667 new Restricted Stock Units.

Castle Biosciences Director Rodney Cotton reported the vesting of 8,673 Restricted Stock Units into common stock and the subsequent grant of 13,667 new Restricted Stock Units.

Kim Caple, a Director at Castle Biosciences Inc., has reported the conversion of previously vested Restricted Stock Units into common stock and the acquisition of a new RSU grant, as detailed in a recent SEC Form 4 filing.

Ellen Goldberg, a Director at Castle Biosciences Inc., has increased her direct beneficial ownership of common stock through RSU vesting and received a new grant of Restricted Stock Units.

Castle Biosciences Director Tiffany Olson has reported the vesting and conversion of restricted stock units into common stock, alongside the grant of new restricted stock units, as part of routine compensation.

Miles Harrison, a Director at Castle Biosciences Inc., reported the conversion of 8,673 vested Restricted Stock Units into common stock and the subsequent grant of 13,667 new Restricted Stock Units.

Director Rodney Cotton acquired 1,952 Restricted Stock Units (RSUs) of Castle Biosciences Inc. on May 8, 2025.

Derek Maetzold, CEO of Castle Biosciences, sold shares of common stock on April 21, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences CEO Derek Maetzold executed multiple sales of common stock on April 8th and 9th, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Director Rodney Cotton exercised stock options on March 26, 2025, acquiring 5,329 shares of Castle Biosciences common stock.

Castle Biosciences CEO Derek Maetzold sold shares of common stock on March 26, 2025, through various trusts, as part of a pre-arranged Rule 10b5-1 trading plan.